Comments
Drug major Cipla today said it has received final approval from the US health regulator for tenofovir disoproxil fumarate tablets, used to treat HIV-1 infections in adults. Cipla in a BSE filing said it has received final approval from the United States Food and Drug Administration (USFDA) for tenofovir disoproxil fumarate tablets, 300 mg.
These tablets are AB-rated generic equivalents of Gilead Sciences’ Viread Tablets, 300 mg, and are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and paediatric patients 12 years of age and older.
Citing IMS Health data, the company said Viread Tablets, 300mg, had US sales of approximately $725 million for the 12-month period ending November 2017. The company’s stock was trading 0.55 per cent higher at Rs 621.55 per scrip on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.